Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Dabigatran and Quinidine Co-administration
NCT02171624Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2009
- Primary completion
- Apr 2009
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of dabigatran in thromboembolism (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Differences between treatments in systolic blood pressure profiles and Incidence of symptomatic hypotension. Started Mar 2009; status: completed.
02
Drugs
dabigatran
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT02171624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171624.